Compare Fortinet Inc (FTNT) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fortinet Inc vs Mesoblast Limited — how do they compare? Fortinet Inc trades at $160.88 (market cap $118.78B), while Mesoblast Limited trades at $16.74 (market cap $2.21B). The key difference: Fortinet Inc is far larger — about 53.7× Mesoblast Limited's market cap, and Fortinet Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| FTNT | MESO | |
|---|---|---|
Market Cap | $118.78B | $2.21B |
Sector | Technology | Technology |
52-Week High | $168.29 | $20.96 |
52-Week Low | $75.23 | $12.88 |
Enterprise Value | $115.21B | $2.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fortinet (FTNT) trades at $161.21, down 1.83% over 24 hours, with a bullish technical signal from moving averages and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $0.90 versus $0.746 expected, driven by robust demand for cybersecurity solutions amid AI-driven security needs. Revenue growth has accelerated from $4.4B in 2022 to $6.8B in 2025, with net income margins above 28%, though valuation ratios like P/E of 57.2 indicate premium pricing.
The outlook remains positive given consistent earnings beats and analyst consensus price target of $174.50, offering ~8% upside. Key risks include high valuation multiples, competitive pressures in cybersecurity, and negative net cash flow trends. Institutional sentiment is mixed with 42.65% buy ratings, but growth in AI security and SASE firewall adoption supports long-term potential.
MESO trades at $16.82, up 0.84% with bullish technical signals from moving averages. The company shows strong revenue growth with Ryoncil generating $115M in its first year, but remains unprofitable with a -144.33% net income margin. Recent developments include positive Phase 3 trial progress and BLA filing for heart failure treatment, supported by analyst consensus leaning bullish with 45% buy ratings.
MESO presents a high-risk, high-reward opportunity with promising commercial traction offset by significant losses. Investment thesis hinges on successful pipeline development and profitability turnaround, while risks include clinical trial outcomes, regulatory approvals, and sustained cash burn requiring careful monitoring of execution milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
